首页> 外文OA文献 >Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups

【2h】

Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups

机译：来自Checkmate 141的两年更新：患有Nivolumab（Nivo）的结果对核和颈部（SCCHN）的复发性或转移性（R / M）鳞状细胞癌（SCCHN）中的反复化或调查仪的选择（IC）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
R.L. Ferris; G.R. Blumenschein; J. Fayette; J. Guigay; A.D. Colevas; L. Licitra; K. Harrington; S. Kasper; E.E. Vokes; C. Even; F. Worden; N.F. Saba; LCIglesias Docampo; R.I. Haddad; T. Rordorf; N. Kiyota; M. Tahara; M. Lynch; L. Li; M. Gillison;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups [J] . Ferris R. L., Blumenschein G. R., Fayette J., International Journal of Radiation Oncology, Biology, Physics . 2018,第5期

机译：来自Checkmate 141的两年更新：患有Nivolumab（Nivo）的结果对核和颈部（SCCHN）的复发性或转移性（R / M）鳞状细胞癌（SCCHN）中的反复化或调查仪的选择（IC）
2. Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups [J] . Ferris R. L., Blumenschein G. R., Fayette J., International Journal of Radiation Oncology, Biology, Physics . 2018,第5期

机译：来自Checkmate 141的两年更新：患有Nivolumab（Nivo）的结果对核和颈部（SCCHN）的复发性或转移性（R / M）鳞状细胞癌（SCCHN）中的反复化或调查仪的选择（IC）
3. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression [J] . Ferris Robert L., Blumenschein George Jr., Fayette Jerome, Oral oncology . 2018,第期

机译：Nivolumab VS调查员在头部和颈部的复发或转移性鳞状细胞癌中的选择：2年的肿瘤PD-L1表达分析了2年的Checkmate 141的疗效更新
4. Up-Regulation of Enhancer of Zeste Homolog 2 Is Associated Positively With Cyclin Dl Overexpression and Poor Clinical Outcome in Head and Neck Squamous Cell Carcinoma [C] . Wei Cao, Zhien Feng, Zhibin Cui, Academic Committee conference of Shanghai key lab of stomatology . 2011

机译：Zeste同源2的增强子的上调与Cyclin Dl过度表达和头颈部鳞状细胞癌的不良临床结果呈正相关。
5. Inflammatory mechanisms of chemokine receptor 7 expression in metastatic squamous cell carcinoma of the head and neck (SCCHN). [D] . Mburu, Yvonne K. 2011

机译：趋化因子受体7在头颈部转移性鳞状细胞癌（SCCHN）中表达的炎症机制。
6. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression [O] . Robert L. Ferris, George Blumenschein Jr., Jerome Fayette, -1

机译：Nivolumab vs研究者在头颈部复发或转移性鳞状细胞癌中的选择：CheckMate 141的2年长期生存更新并通过肿瘤PD-L1表达进行分析
7. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression [O] . Robert L. Ferris, George Blumenschein, Jerome Fayette, 2018

机译：Nivolumab VS调查仪在头部和颈部的复发或转移性鳞状细胞癌中的选择：2年的Checkmate 141的长期存活更新，通过肿瘤PD-L1表达分析

Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups

著录项

相似文献

相关主题

期刊订阅